Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).

Shiva GuptaHyunseon C KangJia SunMarc R MatranaNizar M TannirHaesun Choi

Published in: Abdominal radiology (New York) (2021)

For mRCC patients treated with pazopanib, OS and PFS for PR and SD groups were best predicted by rChoi and mChoi criteria, without or combined with clinical risk factors. 10% threshold criteria also predicted OS and PFS, whereas RECIST did so only in a limited number of patients.

Keyphrases

metastatic renal cell carcinoma
risk factors
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
patient reported outcomes
mesenchymal stem cells